Pharmacy-based screening to detect persons at elevated risk of type 2 diabetes: a cost-utility analysis

BMC Health Services Research

Markku Peltonen¹  Jaana Lindström¹  Piia Lavikainen²  Janne Martikainen²  Emma Aarnio²  Kari Jalkanen²  Tiina Laatikainen³ 

[1] Department of Public Health Solutions, Finnish Institute for Health and Welfare, P.O. Box 30, 00271, Helsinki, Finland;Faculty of Health Sciences, School of Pharmacy, University of Eastern Finland, P.O. Box 1627, 70211, Kuopio, Finland;Institute of Public Health and Clinical Nutrition, University of Eastern Finland, Faculty of Medicine, P.O. Box 1627, 70211, Kuopio, Finland;Chronic Disease Epidemiology and Prevention Unit, Finnish Institute for Health and Welfare, Helsinki, Finland;Joint Municipal Authority for North Karelia Health and Social Services (Siun Sote), Joensuu, Finland;

关键词: Type 2 diabetes;    Pharmacy;    Markov model;    Cost effectiveness analysis;   

DOI  :  10.1186/s12913-021-06948-6

来源: Springer

【 摘 要 】

BackgroundEarly identification of people at elevated risk of type 2 diabetes (T2D) is an important step in preventing or delaying its onset. Pharmacies can serve as a significant channel to reach these people. This study aimed to assess the potential health economic impact of screening and recruitment services in pharmacies in referring people to preventive interventions.MethodsA decision analytic model was constructed to perform a cost-utility analysis of the expected national health economic consequences (in terms of costs and quality-adjusted life years, QALYs) of a hypothetical pharmacy-based service where people screened and recruited through pharmacies would participate in a digital lifestyle program. Cost-effectiveness was considered in terms of net monetary benefit (NMB). In addition, social return on investment (SROI) was calculated as the ratio of the intervention and recruitment costs and the net present value of expected savings. Payback time was the time taken to reach the break-even point in savings. In the base scenario, a 20-year time horizon was applied. Probabilistic and deterministic sensitivity analyses were applied to study robustness of the results.ResultsIn the base scenario, the expected savings from the pharmacy-based screening and recruitment among the reached target cohort were 255.3 m€ (95% CI − 185.2 m€ to 717.2 m€) in pharmacy visiting population meaning 1412€ (95% CI − 1024€ to 3967€) expected savings per person. Additionally, 7032 QALYs (95% CI − 1344 to 16,143) were gained on the population level. The intervention had an NMB of 3358€ (95% CI − 1397€ to 8431€) using a cost-effectiveness threshold of 50,000 €/QALY. The initial costs were 122.2 m€ with an SROI of 2.09€ (95% CI − 1.52€ to 5.88€). The expected payback time was 10 and 8 years for women and men, respectively. Results were most sensitive for changes in effectiveness of the intervention and selected discount rate.ConclusionsT2D screening and recruitment to prevention programs conducted via pharmacies was a dominant option providing both cost savings and QALY gains. The highest savings can be potentially reached by targeting recruitment at men at elevated risk of T2D.

【 授权许可】

CC BY